{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T18:03:29Z","timestamp":1786817009752,"version":"build-2736575974"},"reference-count":20,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Mayo Clinic continued medical education funds"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>A 64-year-old Asian woman diagnosed with synchronous breast ductal carcinoma in situ (DCIS) and stage IV EGFR-mutated non-small cell carcinoma of the lung (NSCLC). A decision was made to defer management of the DCIS and initiate Osimertinib for lung cancer treatment, since this was a life-limiting diagnosis. At 9 months, restaging FDG-PET CT showed an interval response in the NSCLC and complete loss of FDG avidity at the biopsy-proven DCIS site. Breast MRI confirmed complete imaging resolution of the DCIS. The clinical resolution of breast DCIS during third-generation EGFR inhibitor therapy has not been previously reported in humans and highlights a potential role for the EGFR\/HER2 (ERBB) pathway in pre-invasive breast cancer.<\/jats:p>","DOI":"10.3390\/ijms27135995","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:33:06Z","timestamp":1783089186000},"page":"5995","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Complete Imaging Resolution of Ductal Carcinoma In Situ During Osimertinib Therapy for Synchronous EGFR Exon 19-Mutant Non-Small Cell Lung Cancer: A Case Report"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6916-2249","authenticated-orcid":false,"given":"Leticia","family":"Assad Maia Sandoval","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic Arizona, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8309-4863","authenticated-orcid":false,"suffix":"Jr.","given":"Richard E.","family":"Sharpe","sequence":"additional","affiliation":[{"name":"Department of Radiology and Brest Imaging, Mayo Clinic Arizona, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin J.","family":"Fullenkamp","sequence":"additional","affiliation":[{"name":"Department of Radiology and Brest Imaging, Mayo Clinic Arizona, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erinn","family":"Downs","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, Mayo Clinic Arizona, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2606-9922","authenticated-orcid":false,"given":"Lida","family":"Mina","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Mayo Clinic Arizona, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41568-022-00512-y","article-title":"Learning to distinguish progressive and non-progressive ductal carcinoma in situ","volume":"22","author":"Casasent","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.clbc.2023.12.010","article-title":"Update on Management of Ductal Carcinoma in situ","volume":"24","author":"Buchheit","year":"2024","journal-title":"Clin. Breast Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1023\/A:1023958324448","article-title":"EGFR, HER-2\/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast","volume":"79","author":"Lebeau","year":"2003","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_4","first-page":"122","article-title":"Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast","volume":"62","author":"Chan","year":"2002","journal-title":"Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"R76","DOI":"10.1186\/bcr3695","article-title":"Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ","volume":"16","author":"Calvo","year":"2014","journal-title":"Breast Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.20.03570","article-title":"Therapy for Stage IV Non-Small-Cell Lung Cancer with Driver Alterations: ASCO and OH (CCO) Joint Guideline Update","volume":"39","author":"Hanna","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1016\/j.cllc.2023.04.007","article-title":"Characteristics of Patients with Second Primary Lung Cancer Following Breast Cancer: A Retrospective Descriptive Study","volume":"24","author":"Wang","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e7296","DOI":"10.1002\/cam4.7296","article-title":"Clinicopathological features, prognostic factor analysis, and survival nomogram of patients with double primary cancers involving lung cancer","volume":"13","author":"Hao","year":"2024","journal-title":"Cancer Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Song, C., Yu, D., Wang, Y., Wang, Q., Guo, Z., Huang, J., Li, S., and Hu, W. (2020). Dual Primary Cancer Patients with Lung Cancer as a Second Primary Malignancy: A Population-Based Study. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.515606"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Zeng, T., Xu, H., Liu, Y., Sun, C., Yang, F., Liang, Y., Huang, X., Fu, Z., Li, W., and Yin, Y. (2022). High rate of epidermal growth factor receptor-mutated primary lung cancer in patients with primary breast cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.985734"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"805","DOI":"10.33594\/000000174","article-title":"EGFR is a Therapeutic Target in Hormone Receptor-Positive Breast Cancer","volume":"53","author":"Jeong","year":"2019","journal-title":"Cell Physiol. Biochem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1470-2045(05)70176-5","article-title":"Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: A double-blind placebo-controlled phase II randomised trial","volume":"6","author":"Polychronis","year":"2005","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2007.13.5939","article-title":"Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers","volume":"26","author":"Guix","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.breast.2023.07.012","article-title":"The natural history of ductal carcinoma in situ (DCIS) in simulation models: A systematic review","volume":"71","author":"Poelhekken","year":"2023","journal-title":"Breast"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1001\/jama.2024.26698","article-title":"Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial","volume":"333","author":"Hwang","year":"2025","journal-title":"JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1016\/j.jacr.2025.02.027","article-title":"ACR Appropriateness Criteria\u00ae Imaging of Ductal Carcinoma in Situ (DCIS)","volume":"22","author":"Kuzmiak","year":"2025","journal-title":"J. Am. Coll. Radiol."},{"key":"ref_18","first-page":"5871","article-title":"Surgical Resection and Outcome of Synchronous and Metachronous Primary Lung Cancer in Breast Cancer Patients","volume":"37","author":"Shoji","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1056\/NEJMra1703413","article-title":"Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer","volume":"377","author":"Reck","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Yoon, H.Y., Ryu, J.S., Sim, Y.S., Kim, D., Lee, S.Y., Choi, J., Park, S., Ryu, Y.J., Lee, J.H., and Chang, J.H. (2020). Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0228925"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/13\/5995\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:44:43Z","timestamp":1783683883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/13\/5995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":20,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ijms27135995"],"URL":"https:\/\/doi.org\/10.3390\/ijms27135995","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]}}}